Ara-290 10mg 10vials

Description

ARA-290 Innate Repair Receptor Agonist for Neuropathy Research

Product Specifications

• CAS Number: 1208240-50-7
• Molecular Formula: C51H84N16O21
• Molecular Weight: 1257.3 Da
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white sterile lyophilizate

How It Works

The biochemical activity of Ara-290 is defined by its high-specificity interaction with the Innate Repair Receptor (IRR), a heterocomplex consisting of the erythropoietin receptor (EPOR) and the beta-common receptor (CD131). Initially, the peptide binds to the IRR during states of tissue stress or hypoxia. This defines the first semantic triple: [Ara-290 activates the Innate Repair Receptor]. Secondly, this activation initiates a signaling cascade that inhibits the nuclear translocation of NF-kappaB. This establishes the second triple: [IRR signaling suppresses pro-inflammatory cytokines]. Finally, the downstream effect modulates the mitochondrial permeability transition pore to prevent apoptosis. This forms the third triple: [Ara-290 modulates mitochondrial pore transition]. Quantitatively, Ara-290 demonstrates a binding affinity ($K_d$) for the IRR in the low nanomolar range, while its systemic half-life is approximately 20 minutes ($t_{1/2} = 20 pm 5$ min) in research models. Comparative analysis shows that Ara-290 differs from native EPO by lacking affinity for the (EPOR)$_2$ homodimer, thereby ensuring zero impact on red blood cell mass or hematocrit levels.

Compound Background

Ara-290, also known as Cibinetide, is an 11-amino acid peptide meticulously engineered from the B-helix domain of erythropoietin (EPO) to target the Innate Repair Receptor (IRR) selectively. Unlike its parent molecule, Ara-290 is devoid of erythropoietic activity, focusing exclusively on tissue protective and anti-inflammatory signaling pathways. This signaling molecule serves as a critical research tool for investigating the resolution of chronic inflammation and neuropathic injury.

Experimental Outcomes

• Peripheral Nerve Regeneration: Investigators observe a significant reduction in neuropathic sensitivity and improvements in small-fiber nerve density.
• Resolution of Inflammatory Signaling: Experimental findings suggest a marked decrease in systemic biomarkers such as TNF-alpha and IL-6 following administration.
• Enhanced Wound Healing: Per experimental records, research models show accelerated closure of chronic dermal lesions through improved microvascular perfusion.
• Metabolic Optimization: Aggregated data shows localized improvements in glucose disposal and insulin sensitivity in metabolic research models.
• Neuroprotective Resilience: Research models demonstrate a reduction in apoptosis within glial cells subjected to high-stress oxidative environments.

Key Points:
Ara-290 represents a high-feasibility research tool for investigating non-erythropoietic tissue repair and the selective modulation of the innate immune response.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.